MedTrace Logo

Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study

NCT01212731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-04-08

No results posted yet for this study

Summary

The purpose of this study is to:

* estimate the degree of memory loss, if any following radiotherapy to the base of skull or brain as measured by standard neurocognitive battery testing.
* describe radiotherapy dose-related changes in vascular perfusion, in spectroscopic parameters of neuronal injury and changes in the degree and directionality of tissue water diffusivity (diffusion tensor imaging) as a measure of white axonal injury.
* to relate these imaging characteristics to the degree of memory loss.

Conditions

  • Malignancy
  • Glioma
  • Radiotherapy

Interventions

RADIATION

Photon treatment plans

10 of the 30 subjects on Cohort 1 will receive photon treatment plans.

RADIATION

Proton Treatment Plans

20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.

BEHAVIORAL

Neurocognitive evaluation

Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.

DEVICE

Advanced MRI imaging

Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Michelle Alonso Basanta, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2015-08-31
Completion
2017-10-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01212731 on ClinicalTrials.gov